Moomoo AI 已提取核心信息
Avenue Therapeutics, Inc. has announced that stockholders holding approximately 56% of the voting power have approved a reverse stock split of the company's issued and outstanding common stock. The range for the reverse stock split is set between 30-for-1 and 75-for-1, with the exact ratio to be determined by the board of directors. The board unanimously approved the proposal and recommended stockholder approval. The reverse stock split is subject to the board's discretion regarding the timing and necessity of the action. The Information Statement regarding this action was mailed to stockholders on or about a date in 2024, which has not been specified in the announcement. The effective date of the reverse stock split will be no earlier than a date in 2024, also not specified, following the board's determination. This action does not require a stockholder meeting or additional votes, as the written consent already satisfies Delaware law requirements for such corporate actions.
Avenue Therapeutics, Inc. has announced that stockholders holding approximately 56% of the voting power have approved a reverse stock split of the company's issued and outstanding common stock. The range for the reverse stock split is set between 30-for-1 and 75-for-1, with the exact ratio to be determined by the board of directors. The board unanimously approved the proposal and recommended stockholder approval. The reverse stock split is subject to the board's discretion regarding the timing and necessity of the action. The Information Statement regarding this action was mailed to stockholders on or about a date in 2024, which has not been specified in the announcement. The effective date of the reverse stock split will be no earlier than a date in 2024, also not specified, following the board's determination. This action does not require a stockholder meeting or additional votes, as the written consent already satisfies Delaware law requirements for such corporate actions.
Avenue Therapeutics, Inc.宣布，持有约56％投票权的股东已批准对该公司已发行和流通的普通股进行反向股票分割。反向股票拆分的范围设定在30比1和75比1之间，确切的比率将由董事会决定。董事会一致批准了该提案，并建议股东批准。反向股票拆分由董事会自行决定行动的时间和必要性。有关此行动的信息声明是在2024年左右邮寄给股东的，公告中没有具体说明。根据董事会的决定，反向股票拆分的生效日期将不早于2024年的日期，也未具体说明。该行动不需要股东大会或额外投票，因为书面同意已经满足了特拉华州法律对此类公司行为的要求。
Avenue Therapeutics, Inc.宣布，持有约56％投票权的股东已批准对该公司已发行和流通的普通股进行反向股票分割。反向股票拆分的范围设定在30比1和75比1之间，确切的比率将由董事会决定。董事会一致批准了该提案，并建议股东批准。反向股票拆分由董事会自行决定行动的时间和必要性。有关此行动的信息声明是在2024年左右邮寄给股东的，公告中没有具体说明。根据董事会的决定，反向股票拆分的生效日期将不早于2024年的日期，也未具体说明。该行动不需要股东大会或额外投票，因为书面同意已经满足了特拉华州法律对此类公司行为的要求。
有用
没用
